What Is the Treatment of Pleural Tuberculosis?
Pleural tuberculosis is an extrapulmonary form of tuberculosis that affects the pleural space. It is treated with a structured first-line regimen in line with WHO guidelines for extrapulmonary TB.
Clinical Goals
The primary indicators of effective treatment are improvement in the classic symptoms of TB — including cough and fever — and weight gain. These responses are typically expected within the first one to two months of effective therapy.
Treatment Approach
Management centres on a combination antimicrobial regimen structured in sequential phases, with specific criteria governing drug selection based on individual patient profile.
Full drug selection criteria, dosing guidance, phase durations, and clinical decision points are in the structured protocol below.
References
- This 6-month treatment regimen, 2HRZ(E)/4HR, comprises isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months followed by isoniazid and rifampicin for 4 months.
- Adults with extrapulmonary TB are eligible for the 6-month 2HRZE/4HR regimen, except for those with TB of the central nervous system, bone or joint, for which some expert groups suggest longer therapy (i.e. 9–12 months).
- In children (usually defined as being aged <10 years) in settings with a high background prevalence of isoniazid resistance or HIV infection, or in CLHIV, ethambutol should be used in the first 2 months of treatment; in all other situations ethambutol can be omitted, resulting in a 2HRZ/4HR regimen.
- The classic symptoms of TB – cough, sputum production, fever and weight loss – generally improve within the first few weeks of treatment.
- Cough and sputum production can persist after sputum conversion in patients with extensive lung damage (often due to late diagnosis), but even in those with extensive lung damage, improvement is usually seen within 1–2 months of effective treatment.
View source ↗